Commentary: Drawbacks of cost-effectiveness tests

01/20/2009 | Wall Street Journal (free content), The

House Democrats proposed forming an entity that would determine the cost effectiveness of drugs and devices being considered for Medicare and Medicaid coverage. This suggestion fails to take into account disease variation and other scientific factors that influence treatment decisions, Dr. Scott Gottlieb writes. He recommends that the government consider guidelines from medical groups in weighing rival technology and that the FDA allow private firms to use findings from their comparative studies to promote products to expert buyers.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD